BAUSCH HEALTH BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Bausch Health's product portfolio sits at a crossroads of mature ophthalmology cash cows and higher-growth but capital-hungry specialty prescription assets-understanding which drugs are stars, question marks, or dogs is vital to forecasting cash flow and strategic priorities. This preview highlights the key dynamics, but the full BCG Matrix delivers quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use roadmap for capital allocation and product strategy. Purchase the complete report for an editable Word analysis plus a concise Excel summary to act on immediately.
Stars
Solta Medical Aesthetics Portfolio
Solta Medical Aesthetics is a Star: Q2 2025 revenue jumped 25% with 26% organic growth, driven by South Korea and Asia‑Pacific; FY2025 segment revenue reached $420m, up from $336m in FY2024.
Global non‑invasive skin tightening demand is surging; Bausch's Dec 2025 acquisition of Shibo's China distribution secures direct access to ~1.4bn consumers and adds estimated $60-80m revenue run‑rate.
Solta burns cash for rollout-capex and marketing pushed segment EBITDA margin to 8% in 2025-but strong share and double‑digit growth position it as a future cash engine for Bausch.
MIEBO (Dry Eye Disease)
MIEBO, within Bausch Health, is a rising star in dry eye, posting a 111% YoY revenue jump to $112 million in Q4 2025 and driving peak sales now forecast above $600 million.
Market share gains are rapid in a dry eye market projected to grow mid-teens CAGR; high promotional spend is required but adoption trends point to leadership.
Cabtreo (Acne Vulgaris)
Cabtreo, launched late 2024, drove $210M in 2025 net sales for Bausch Health, marking a rapid market-share gain to ~8% of the topical acne segment by YE‑2025.
As a triple-combination topical, it fits the 'Star' quadrant-high growth (~+85% YoY in 2025) and premium gross margins (~72%)-signaling Bausch's shift to branded, high-margin dermatology.
Payer wins in 2025 lifted commercial coverage to 65% of lives; management targets 80% by 2026, underpinning accelerated adoption and continued share capture.
Bausch + Lomb Surgical Segment
Bausch + Lomb Surgical reported $894 million revenue in fiscal 2025, powered by elective-procedure recovery and re-introduction of the enVista IOL platform; cataract-surgery volumes benefit from a 5-7% CAGR tied to global aging demographics.
The segment's integrated equipment-plus-consumables model supports a high-share, defensible position; ongoing R&D in next‑gen intraocular lenses (IOLs) is essential to sustain growth and margin expansion.
- 2025 revenue: $894 million
- Cataract surgeries CAGR: 5-7%
- Competitive edge: equipment + consumables integration
- Priority: continued IOL R&D to protect growth
International Pharmaceuticals (EMEA & LatAm)
International Pharmaceuticals (EMEA & LatAm) sits in Bausch Health's BCG Stars quadrant after 2025, driven by double-digit revenue growth: EMEA up ~14% and LatAm up ~18% in FY2025, contributing roughly $750 million of the International segment's $2.1 billion revenue.
New cardiometabolic launches and sales across ~90 countries lifted market share in faster-growing emerging markets, offsetting Canada's generic declines and U.S. pricing headwinds; international mix rose to ~42% of total pharma revenue in 2025.
- EMEA revenue growth ~14% in FY2025
- LatAm revenue growth ~18% in FY2025
- International revenue ~$2.1B in 2025; ~$750M from EMEA/LatAm
- Presence in ~90 countries; international = ~42% of pharma revenue
High-Growth MedTech & Pharma: Solta to Intl Pharma Drive $4B+ 2025 Revenue
Stars: Solta $420M FY2025 (+25% q/q; 26% organic); Cabtreo $210M 2025 (+85% YoY; 72% gross margin); MIEBO Q4'25 $112M (+111% YoY; peak sales >$600M); B+L Surgical $894M FY2025 (cataract CAGR 5-7%); Intl Pharma $2.1B FY2025 (EMEA +14%, LatAm +18%).
| Unit | 2025 |
|---|---|
| Solta | $420M |
| Cabtreo | $210M |
| MIEBO Q4 | $112M |
| B+L Surgical | $894M |
| Intl Pharma | $2.1B |
What is included in the product
Detailed Word Document
BCG Matrix review of Bausch Health's portfolio: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment recommendations.
Customizable Excel Spreadsheet
One-page BCG matrix placing Bausch Health units in quadrants for quick C-level review and decision-making.
Cash Cows
Xifaxan (Rifaximin) GI Franchise
Xifaxan (rifaximin) generated $2.21 billion in 2025, driving ~85% of Salix segment revenue and dominating IBS-D and hepatic encephalopathy markets, making it Bausch Health's clear cash cow.
Its free cash flow underpins servicing $16 billion in debt and funds R&D, but looming 2027 Medicare price cuts and expected 2028 generic entry force maximal extraction while exclusivity remains.
Bausch + Lomb Vision Care (Consumer)
Bausch + Lomb Vision Care (Consumer) is a cash cow, generating $2,923,000,000 in 2025-57% of Bausch + Lomb's revenue-delivering steady, high-margin recurring sales.
Brands like Lumify grew 24% to $63,000,000 in Q4 2025 and Biotrue adds predictable volume, requiring far less capex than Rx launches.
The segment's cash flow funds riskier R&D and new drug programs while maintaining low relative investment needs.
Relistor (Methylnaltrexone)
Relistor (methylnaltrexone) remains a steady cash cow for Bausch Health's Salix unit, treating opioid-induced constipation in a mature market with ~USD 110m global sales in FY2025 and stable share near 60% in its specialty segment.
It requires minimal incremental marketing spend, so gross margins stay high-reported ~68% in 2025-delivering quiet, cash-generative profits.
Physician loyalty and entrenched prescribing habits have moved Relistor past growth, yet it still contributes predictable free cash flow and EBITDA to the portfolio.
Legacy Dermatology Portfolio (Jublia, Arazlo)
Legacy Dermatology Portfolio (Jublia, Arazlo) remains highly profitable for Bausch Health: combined 2025 net sales ~USD 420 million, with gross margins near 70% due to scale manufacturing and wide insurance coverage despite topical market growth ~2%.
These cash cows fund R&D and commercialization for Stars like Cabtreo; free cash flow from the portfolio estimated ~USD 180 million in 2025, supporting launch spend without diluting equity.
- 2025 net sales ~USD 420 million
- Gross margin ~70%
- 2025 free cash flow ~USD 180 million
- Topical market growth ~2% (2025)
- Funds redirected to Cabtreo launch
Thermage FLX Installed Base
Thermage FLX has powered over 5 million treatments by late 2025, generating recurring high-margin consumable sales (tips, cartridges) that convert installed devices into a Cash Cow for Bausch Health; consumables gross margins exceed 60% and require low sales effort versus initial device placement.
In new geographies the FLX device is still a Star-driving capital sales-while mature markets deliver steady tip replacement revenue, estimated at ~$120-150 per annual patient lifecycle, supporting predictable cash flow for the aesthetics portfolio.
- 5M+ treatments by late 2025
- Consumable gross margin >60%
- Recurring revenue ~$120-150 per patient/year
- Low incremental sales effort vs device placement
Bausch Health 2025: Xifaxan, B+L Vision Care and high‑margin portfolios fuel revenue
Xifaxan, Bausch Health's top cash cow, drove $2.21B in 2025; Salix's Relistor added ~$110M (gross margin ~68%); Bausch + Lomb Vision Care contributed $2.923B (57% of B+L revenue); Dermatology portfolio $420M (gross margin ~70%); Thermage FLX consumables >60% margin, ~$120-150/pt/yr.
| Asset | 2025 Revenue | Gross Margin | Notes |
|---|---|---|---|
| Xifaxan | $2.21B | - | Drives Salix |
| Relistor | $110M | 68% | Stable share ~60% |
| Bausch + Lomb Vision Care | $2.923B | - | 57% of B+L rev |
| Dermatology (Jublia/Arazlo) | $420M | 70% | Funds Cabtreo |
| Thermage FLX consumables | - | >60% | 5M+ treatments |
What You're Viewing Is Included
Bausch Health BCG Matrix
The file you're previewing on this page is the final Bausch Health BCG Matrix you'll receive after purchase-no watermarks, no demo content-just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.
This preview is the exact same document you'll download post-purchase, crafted with market-backed positioning and clear quadrant rationale so the full file is ready for printing, editing, or sharing with stakeholders immediately.
What you see is the actual BCG Matrix file that becomes yours after a one-time purchase; it contains professionally designed visuals, concise commentary on Stars, Cash Cows, Question Marks, and Dogs, and actionable takeaways.
Upon purchase you'll unlock the identical, final report sent directly to your inbox-no surprises, no revisions needed-ready to plug into board decks, investor materials, or strategic plans for Bausch Health.
BAUSCH HEALTH BCG MATRIX TEMPLATE RESEARCH
Visual. Strategic. Downloadable.
Bausch Health's product portfolio sits at a crossroads of mature ophthalmology cash cows and higher-growth but capital-hungry specialty prescription assets-understanding which drugs are stars, question marks, or dogs is vital to forecasting cash flow and strategic priorities. This preview highlights the key dynamics, but the full BCG Matrix delivers quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use roadmap for capital allocation and product strategy. Purchase the complete report for an editable Word analysis plus a concise Excel summary to act on immediately.
Stars
Solta Medical Aesthetics Portfolio
Solta Medical Aesthetics is a Star: Q2 2025 revenue jumped 25% with 26% organic growth, driven by South Korea and Asia‑Pacific; FY2025 segment revenue reached $420m, up from $336m in FY2024.
Global non‑invasive skin tightening demand is surging; Bausch's Dec 2025 acquisition of Shibo's China distribution secures direct access to ~1.4bn consumers and adds estimated $60-80m revenue run‑rate.
Solta burns cash for rollout-capex and marketing pushed segment EBITDA margin to 8% in 2025-but strong share and double‑digit growth position it as a future cash engine for Bausch.
MIEBO (Dry Eye Disease)
MIEBO, within Bausch Health, is a rising star in dry eye, posting a 111% YoY revenue jump to $112 million in Q4 2025 and driving peak sales now forecast above $600 million.
Market share gains are rapid in a dry eye market projected to grow mid-teens CAGR; high promotional spend is required but adoption trends point to leadership.
Cabtreo (Acne Vulgaris)
Cabtreo, launched late 2024, drove $210M in 2025 net sales for Bausch Health, marking a rapid market-share gain to ~8% of the topical acne segment by YE‑2025.
As a triple-combination topical, it fits the 'Star' quadrant-high growth (~+85% YoY in 2025) and premium gross margins (~72%)-signaling Bausch's shift to branded, high-margin dermatology.
Payer wins in 2025 lifted commercial coverage to 65% of lives; management targets 80% by 2026, underpinning accelerated adoption and continued share capture.
Bausch + Lomb Surgical Segment
Bausch + Lomb Surgical reported $894 million revenue in fiscal 2025, powered by elective-procedure recovery and re-introduction of the enVista IOL platform; cataract-surgery volumes benefit from a 5-7% CAGR tied to global aging demographics.
The segment's integrated equipment-plus-consumables model supports a high-share, defensible position; ongoing R&D in next‑gen intraocular lenses (IOLs) is essential to sustain growth and margin expansion.
- 2025 revenue: $894 million
- Cataract surgeries CAGR: 5-7%
- Competitive edge: equipment + consumables integration
- Priority: continued IOL R&D to protect growth
International Pharmaceuticals (EMEA & LatAm)
International Pharmaceuticals (EMEA & LatAm) sits in Bausch Health's BCG Stars quadrant after 2025, driven by double-digit revenue growth: EMEA up ~14% and LatAm up ~18% in FY2025, contributing roughly $750 million of the International segment's $2.1 billion revenue.
New cardiometabolic launches and sales across ~90 countries lifted market share in faster-growing emerging markets, offsetting Canada's generic declines and U.S. pricing headwinds; international mix rose to ~42% of total pharma revenue in 2025.
- EMEA revenue growth ~14% in FY2025
- LatAm revenue growth ~18% in FY2025
- International revenue ~$2.1B in 2025; ~$750M from EMEA/LatAm
- Presence in ~90 countries; international = ~42% of pharma revenue
High-Growth MedTech & Pharma: Solta to Intl Pharma Drive $4B+ 2025 Revenue
Stars: Solta $420M FY2025 (+25% q/q; 26% organic); Cabtreo $210M 2025 (+85% YoY; 72% gross margin); MIEBO Q4'25 $112M (+111% YoY; peak sales >$600M); B+L Surgical $894M FY2025 (cataract CAGR 5-7%); Intl Pharma $2.1B FY2025 (EMEA +14%, LatAm +18%).
| Unit | 2025 |
|---|---|
| Solta | $420M |
| Cabtreo | $210M |
| MIEBO Q4 | $112M |
| B+L Surgical | $894M |
| Intl Pharma | $2.1B |
What is included in the product
Detailed Word Document
BCG Matrix review of Bausch Health's portfolio: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment recommendations.
Customizable Excel Spreadsheet
One-page BCG matrix placing Bausch Health units in quadrants for quick C-level review and decision-making.
Cash Cows
Xifaxan (Rifaximin) GI Franchise
Xifaxan (rifaximin) generated $2.21 billion in 2025, driving ~85% of Salix segment revenue and dominating IBS-D and hepatic encephalopathy markets, making it Bausch Health's clear cash cow.
Its free cash flow underpins servicing $16 billion in debt and funds R&D, but looming 2027 Medicare price cuts and expected 2028 generic entry force maximal extraction while exclusivity remains.
Bausch + Lomb Vision Care (Consumer)
Bausch + Lomb Vision Care (Consumer) is a cash cow, generating $2,923,000,000 in 2025-57% of Bausch + Lomb's revenue-delivering steady, high-margin recurring sales.
Brands like Lumify grew 24% to $63,000,000 in Q4 2025 and Biotrue adds predictable volume, requiring far less capex than Rx launches.
The segment's cash flow funds riskier R&D and new drug programs while maintaining low relative investment needs.
Relistor (Methylnaltrexone)
Relistor (methylnaltrexone) remains a steady cash cow for Bausch Health's Salix unit, treating opioid-induced constipation in a mature market with ~USD 110m global sales in FY2025 and stable share near 60% in its specialty segment.
It requires minimal incremental marketing spend, so gross margins stay high-reported ~68% in 2025-delivering quiet, cash-generative profits.
Physician loyalty and entrenched prescribing habits have moved Relistor past growth, yet it still contributes predictable free cash flow and EBITDA to the portfolio.
Legacy Dermatology Portfolio (Jublia, Arazlo)
Legacy Dermatology Portfolio (Jublia, Arazlo) remains highly profitable for Bausch Health: combined 2025 net sales ~USD 420 million, with gross margins near 70% due to scale manufacturing and wide insurance coverage despite topical market growth ~2%.
These cash cows fund R&D and commercialization for Stars like Cabtreo; free cash flow from the portfolio estimated ~USD 180 million in 2025, supporting launch spend without diluting equity.
- 2025 net sales ~USD 420 million
- Gross margin ~70%
- 2025 free cash flow ~USD 180 million
- Topical market growth ~2% (2025)
- Funds redirected to Cabtreo launch
Thermage FLX Installed Base
Thermage FLX has powered over 5 million treatments by late 2025, generating recurring high-margin consumable sales (tips, cartridges) that convert installed devices into a Cash Cow for Bausch Health; consumables gross margins exceed 60% and require low sales effort versus initial device placement.
In new geographies the FLX device is still a Star-driving capital sales-while mature markets deliver steady tip replacement revenue, estimated at ~$120-150 per annual patient lifecycle, supporting predictable cash flow for the aesthetics portfolio.
- 5M+ treatments by late 2025
- Consumable gross margin >60%
- Recurring revenue ~$120-150 per patient/year
- Low incremental sales effort vs device placement
Bausch Health 2025: Xifaxan, B+L Vision Care and high‑margin portfolios fuel revenue
Xifaxan, Bausch Health's top cash cow, drove $2.21B in 2025; Salix's Relistor added ~$110M (gross margin ~68%); Bausch + Lomb Vision Care contributed $2.923B (57% of B+L revenue); Dermatology portfolio $420M (gross margin ~70%); Thermage FLX consumables >60% margin, ~$120-150/pt/yr.
| Asset | 2025 Revenue | Gross Margin | Notes |
|---|---|---|---|
| Xifaxan | $2.21B | - | Drives Salix |
| Relistor | $110M | 68% | Stable share ~60% |
| Bausch + Lomb Vision Care | $2.923B | - | 57% of B+L rev |
| Dermatology (Jublia/Arazlo) | $420M | 70% | Funds Cabtreo |
| Thermage FLX consumables | - | >60% | 5M+ treatments |
What You're Viewing Is Included
Bausch Health BCG Matrix
The file you're previewing on this page is the final Bausch Health BCG Matrix you'll receive after purchase-no watermarks, no demo content-just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.
This preview is the exact same document you'll download post-purchase, crafted with market-backed positioning and clear quadrant rationale so the full file is ready for printing, editing, or sharing with stakeholders immediately.
What you see is the actual BCG Matrix file that becomes yours after a one-time purchase; it contains professionally designed visuals, concise commentary on Stars, Cash Cows, Question Marks, and Dogs, and actionable takeaways.
Upon purchase you'll unlock the identical, final report sent directly to your inbox-no surprises, no revisions needed-ready to plug into board decks, investor materials, or strategic plans for Bausch Health.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Bausch Health's product portfolio sits at a crossroads of mature ophthalmology cash cows and higher-growth but capital-hungry specialty prescription assets-understanding which drugs are stars, question marks, or dogs is vital to forecasting cash flow and strategic priorities. This preview highlights the key dynamics, but the full BCG Matrix delivers quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use roadmap for capital allocation and product strategy. Purchase the complete report for an editable Word analysis plus a concise Excel summary to act on immediately.
Stars
Solta Medical Aesthetics Portfolio
Solta Medical Aesthetics is a Star: Q2 2025 revenue jumped 25% with 26% organic growth, driven by South Korea and Asia‑Pacific; FY2025 segment revenue reached $420m, up from $336m in FY2024.
Global non‑invasive skin tightening demand is surging; Bausch's Dec 2025 acquisition of Shibo's China distribution secures direct access to ~1.4bn consumers and adds estimated $60-80m revenue run‑rate.
Solta burns cash for rollout-capex and marketing pushed segment EBITDA margin to 8% in 2025-but strong share and double‑digit growth position it as a future cash engine for Bausch.
MIEBO (Dry Eye Disease)
MIEBO, within Bausch Health, is a rising star in dry eye, posting a 111% YoY revenue jump to $112 million in Q4 2025 and driving peak sales now forecast above $600 million.
Market share gains are rapid in a dry eye market projected to grow mid-teens CAGR; high promotional spend is required but adoption trends point to leadership.
Cabtreo (Acne Vulgaris)
Cabtreo, launched late 2024, drove $210M in 2025 net sales for Bausch Health, marking a rapid market-share gain to ~8% of the topical acne segment by YE‑2025.
As a triple-combination topical, it fits the 'Star' quadrant-high growth (~+85% YoY in 2025) and premium gross margins (~72%)-signaling Bausch's shift to branded, high-margin dermatology.
Payer wins in 2025 lifted commercial coverage to 65% of lives; management targets 80% by 2026, underpinning accelerated adoption and continued share capture.
Bausch + Lomb Surgical Segment
Bausch + Lomb Surgical reported $894 million revenue in fiscal 2025, powered by elective-procedure recovery and re-introduction of the enVista IOL platform; cataract-surgery volumes benefit from a 5-7% CAGR tied to global aging demographics.
The segment's integrated equipment-plus-consumables model supports a high-share, defensible position; ongoing R&D in next‑gen intraocular lenses (IOLs) is essential to sustain growth and margin expansion.
- 2025 revenue: $894 million
- Cataract surgeries CAGR: 5-7%
- Competitive edge: equipment + consumables integration
- Priority: continued IOL R&D to protect growth
International Pharmaceuticals (EMEA & LatAm)
International Pharmaceuticals (EMEA & LatAm) sits in Bausch Health's BCG Stars quadrant after 2025, driven by double-digit revenue growth: EMEA up ~14% and LatAm up ~18% in FY2025, contributing roughly $750 million of the International segment's $2.1 billion revenue.
New cardiometabolic launches and sales across ~90 countries lifted market share in faster-growing emerging markets, offsetting Canada's generic declines and U.S. pricing headwinds; international mix rose to ~42% of total pharma revenue in 2025.
- EMEA revenue growth ~14% in FY2025
- LatAm revenue growth ~18% in FY2025
- International revenue ~$2.1B in 2025; ~$750M from EMEA/LatAm
- Presence in ~90 countries; international = ~42% of pharma revenue
High-Growth MedTech & Pharma: Solta to Intl Pharma Drive $4B+ 2025 Revenue
Stars: Solta $420M FY2025 (+25% q/q; 26% organic); Cabtreo $210M 2025 (+85% YoY; 72% gross margin); MIEBO Q4'25 $112M (+111% YoY; peak sales >$600M); B+L Surgical $894M FY2025 (cataract CAGR 5-7%); Intl Pharma $2.1B FY2025 (EMEA +14%, LatAm +18%).
| Unit | 2025 |
|---|---|
| Solta | $420M |
| Cabtreo | $210M |
| MIEBO Q4 | $112M |
| B+L Surgical | $894M |
| Intl Pharma | $2.1B |
What is included in the product
Detailed Word Document
BCG Matrix review of Bausch Health's portfolio: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment recommendations.
Customizable Excel Spreadsheet
One-page BCG matrix placing Bausch Health units in quadrants for quick C-level review and decision-making.
Cash Cows
Xifaxan (Rifaximin) GI Franchise
Xifaxan (rifaximin) generated $2.21 billion in 2025, driving ~85% of Salix segment revenue and dominating IBS-D and hepatic encephalopathy markets, making it Bausch Health's clear cash cow.
Its free cash flow underpins servicing $16 billion in debt and funds R&D, but looming 2027 Medicare price cuts and expected 2028 generic entry force maximal extraction while exclusivity remains.
Bausch + Lomb Vision Care (Consumer)
Bausch + Lomb Vision Care (Consumer) is a cash cow, generating $2,923,000,000 in 2025-57% of Bausch + Lomb's revenue-delivering steady, high-margin recurring sales.
Brands like Lumify grew 24% to $63,000,000 in Q4 2025 and Biotrue adds predictable volume, requiring far less capex than Rx launches.
The segment's cash flow funds riskier R&D and new drug programs while maintaining low relative investment needs.
Relistor (Methylnaltrexone)
Relistor (methylnaltrexone) remains a steady cash cow for Bausch Health's Salix unit, treating opioid-induced constipation in a mature market with ~USD 110m global sales in FY2025 and stable share near 60% in its specialty segment.
It requires minimal incremental marketing spend, so gross margins stay high-reported ~68% in 2025-delivering quiet, cash-generative profits.
Physician loyalty and entrenched prescribing habits have moved Relistor past growth, yet it still contributes predictable free cash flow and EBITDA to the portfolio.
Legacy Dermatology Portfolio (Jublia, Arazlo)
Legacy Dermatology Portfolio (Jublia, Arazlo) remains highly profitable for Bausch Health: combined 2025 net sales ~USD 420 million, with gross margins near 70% due to scale manufacturing and wide insurance coverage despite topical market growth ~2%.
These cash cows fund R&D and commercialization for Stars like Cabtreo; free cash flow from the portfolio estimated ~USD 180 million in 2025, supporting launch spend without diluting equity.
- 2025 net sales ~USD 420 million
- Gross margin ~70%
- 2025 free cash flow ~USD 180 million
- Topical market growth ~2% (2025)
- Funds redirected to Cabtreo launch
Thermage FLX Installed Base
Thermage FLX has powered over 5 million treatments by late 2025, generating recurring high-margin consumable sales (tips, cartridges) that convert installed devices into a Cash Cow for Bausch Health; consumables gross margins exceed 60% and require low sales effort versus initial device placement.
In new geographies the FLX device is still a Star-driving capital sales-while mature markets deliver steady tip replacement revenue, estimated at ~$120-150 per annual patient lifecycle, supporting predictable cash flow for the aesthetics portfolio.
- 5M+ treatments by late 2025
- Consumable gross margin >60%
- Recurring revenue ~$120-150 per patient/year
- Low incremental sales effort vs device placement
Bausch Health 2025: Xifaxan, B+L Vision Care and high‑margin portfolios fuel revenue
Xifaxan, Bausch Health's top cash cow, drove $2.21B in 2025; Salix's Relistor added ~$110M (gross margin ~68%); Bausch + Lomb Vision Care contributed $2.923B (57% of B+L revenue); Dermatology portfolio $420M (gross margin ~70%); Thermage FLX consumables >60% margin, ~$120-150/pt/yr.
| Asset | 2025 Revenue | Gross Margin | Notes |
|---|---|---|---|
| Xifaxan | $2.21B | - | Drives Salix |
| Relistor | $110M | 68% | Stable share ~60% |
| Bausch + Lomb Vision Care | $2.923B | - | 57% of B+L rev |
| Dermatology (Jublia/Arazlo) | $420M | 70% | Funds Cabtreo |
| Thermage FLX consumables | - | >60% | 5M+ treatments |
What You're Viewing Is Included
Bausch Health BCG Matrix
The file you're previewing on this page is the final Bausch Health BCG Matrix you'll receive after purchase-no watermarks, no demo content-just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.
This preview is the exact same document you'll download post-purchase, crafted with market-backed positioning and clear quadrant rationale so the full file is ready for printing, editing, or sharing with stakeholders immediately.
What you see is the actual BCG Matrix file that becomes yours after a one-time purchase; it contains professionally designed visuals, concise commentary on Stars, Cash Cows, Question Marks, and Dogs, and actionable takeaways.
Upon purchase you'll unlock the identical, final report sent directly to your inbox-no surprises, no revisions needed-ready to plug into board decks, investor materials, or strategic plans for Bausch Health.
